BetterLife Pharma (NPAU) AI Stock Analysis

BetterLife Pharma

(Frankfurt:NPAU)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Pipeline and intellectual property focusThe company is focused on developing drug candidates for mental health and neurological indications, with activities centered on clinical and preclinical programs and related intellectual property. Progress in these assets could create future commercial opportunities beyond the current development stage.

Negative Factors

No reported revenueThe absence of reported revenue means the company currently lacks an established commercial income stream to support research, development, and corporate expenses. Until commercialization or another revenue source emerges, financial progress remains dependent on pipeline advancement and outside funding.

BetterLife Pharma (NPAU) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 111.24M
Dividend Yield: ―
Average Volume (3M): 19.54K
Price to Earnings (P/E): -11.4
Beta (1Y): 1.19
Revenue Growth: ―
EPS Growth: -248.72%
Country: Germany
Employees: 4
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

BetterLife Pharma Business Overview & Revenue Model

Company Description

BetterLife Pharma Inc. is a biotechnology company focused on the global development and commercialization of therapeutic compounds, particularly for neurological disorders. The firm also innovates drug candidates utilizing complementary interferon-ba...

BetterLife Pharma Risk Analysis

BetterLife Pharma disclosed 20 risk factors in its most recent earnings report. BetterLife Pharma reported the most risks in the "Finance & Corporate" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

0 New Risks

BetterLife Pharma Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:NPAU against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
TSE:MDMA	50Neutral	CAD 18.57M	-11.41	-72.15%	―	224.46%	28.37%
TSE:PHRM	48Neutral	CAD 5.01M	-13.10	-75.59%	―	―	75.84%
TSE:MRVL	46Neutral	CAD 7.56M	-4.49	39.05%	―	―	25.70%
TSE:CSCI	42Neutral	CAD 8.37M	-0.46	-48.52%	―	-13.00%	75.31%
TSE:MOOD	42Neutral	CAD 680.99K	-0.57	-85.01%	―	73.76%	-108.30%

* Healthcare Sector Average

Performance Comparison

DE:NPAU and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:NPAU	Betterlife Pharma Inc.	0.15	0.12	354.55%
TSE:CSCI	Cosciens Biopharma Inc.	8.40	-2.31	-21.57%
TSE:PHRM	PharmaTher Holdings Ltd	0.06	-0.06	-50.00%
TSE:MRVL	Marvel Biosciences Corp	0.12	-0.10	-45.45%
TSE:MOOD	Doseology Sciences, Inc.	0.09	-0.26	-75.71%
TSE:MDMA	PharmAla Biotech Holdings, Inc.	0.17	0.05	41.67%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

BetterLife Pharma AI Stock Analysis